188 related articles for article (PubMed ID: 19505899)
1. Apoptosis in the colonic crypt, colorectal adenomata, and manipulation by chemoprevention.
West NJ; Courtney ED; Poullis AP; Leicester RJ
Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1680-7. PubMed ID: 19505899
[TBL] [Abstract][Full Text] [Related]
2. Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial".
Stevens RG; Pretlow TP; Hurlstone DP; Giardina C; Rosenberg DW
Cancer Prev Res (Phila); 2008 Aug; 1(3):215-6; author reply 216. PubMed ID: 19138959
[No Abstract] [Full Text] [Related]
3. Aberrant crypt foci and beta-catenin accumulated crypts; significance and roles for colorectal carcinogenesis.
Mori H; Yamada Y; Kuno T; Hirose Y
Mutat Res; 2004 May; 566(3):191-208. PubMed ID: 15082237
[TBL] [Abstract][Full Text] [Related]
4. [Aberrant crypt foci as biomarkers in chemoprevention for colorectal cancer].
Katsuki S; Oui M; Takayama T; Takahashi Y; Shuichi N; Niitsu Y
Nihon Geka Gakkai Zasshi; 1998 Jun; 99(6):379-84. PubMed ID: 9695076
[TBL] [Abstract][Full Text] [Related]
5. Progressive cellular response in the lamina propria of the colorectal adenoma-carcinoma sequence.
Cui G; Yuan A; Vonen B; Florholmen J
Histopathology; 2009 Apr; 54(5):550-60. PubMed ID: 19413637
[TBL] [Abstract][Full Text] [Related]
6. Endoscopy, morphology, morphometry and molecular markers: predicting cancer risk in colorectal adenoma.
Søreide K; Nedrebø BS; Reite A; Thorsen K; Kørner H
Expert Rev Mol Diagn; 2009 Mar; 9(2):125-37. PubMed ID: 19298137
[TBL] [Abstract][Full Text] [Related]
7. Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention.
Lance P; Hamilton SR
Cancer Prev Res (Phila); 2008 Jun; 1(1):4-8. PubMed ID: 19138929
[No Abstract] [Full Text] [Related]
8. Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials.
Einspahr JG; Alberts DS; Gapstur SM; Bostick RM; Emerson SS; Gerner EW
Cancer Epidemiol Biomarkers Prev; 1997 Jan; 6(1):37-48. PubMed ID: 8993796
[TBL] [Abstract][Full Text] [Related]
9. [Pathomorphologic diagnostic guidelines for colon polyps].
Trawiński J; Patera J; Stanek-Widera A; Koktysz R; Kozłowski W
Pol Merkur Lekarski; 2007 May; 22(131):454-6. PubMed ID: 17679394
[TBL] [Abstract][Full Text] [Related]
10. Lack of chemoprevention of dietary Agaricus blazei against rat colonic aberrant crypt foci.
Ziliotto L; Barbisan LF; Rodrigues MA
Hum Exp Toxicol; 2008 Jun; 27(6):505-11. PubMed ID: 18784204
[TBL] [Abstract][Full Text] [Related]
11. Aberrant crypt foci: are they intermediate endpoints of colon carcinogenesis in humans?
Gupta AK; Schoen RE
Curr Opin Gastroenterol; 2009 Jan; 25(1):59-65. PubMed ID: 19114775
[TBL] [Abstract][Full Text] [Related]
12. Is the demonstration of adenoma reduction with rofecoxib a pyrrhic victory?
Lynch PM
Gastroenterology; 2006 Dec; 131(6):2003-5. PubMed ID: 17188962
[No Abstract] [Full Text] [Related]
13. mTOR signaling pathway is a target for the treatment of colorectal cancer.
Zhang YJ; Dai Q; Sun DF; Xiong H; Tian XQ; Gao FH; Xu MH; Chen GQ; Han ZG; Fang JY
Ann Surg Oncol; 2009 Sep; 16(9):2617-28. PubMed ID: 19517193
[TBL] [Abstract][Full Text] [Related]
14. Altered expression of apoptosis biomarkers in human colorectal microadenomas.
Sena P; Roncucci L; Marzona L; Mariani F; Maffei S; Manenti A; De Pol A
Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):351-7. PubMed ID: 20142237
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers for early detection of colon cancer.
Srivastava S; Verma M; Henson DE
Clin Cancer Res; 2001 May; 7(5):1118-26. PubMed ID: 11350874
[TBL] [Abstract][Full Text] [Related]
16. Screening for colorectal cancer: does it all start with aberrant crypt foci?
Rasheed S; Rigas B
Gastrointest Endosc; 2008 Jun; 67(7):1103-5. PubMed ID: 18513552
[No Abstract] [Full Text] [Related]
17. Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers.
Armstrong WB; Taylor TH; Meyskens FL
Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):589-92. PubMed ID: 12869395
[No Abstract] [Full Text] [Related]
18. Aberrant crypt foci: what we know and what we need to know.
Gupta AK; Pretlow TP; Schoen RE
Clin Gastroenterol Hepatol; 2007 May; 5(5):526-33. PubMed ID: 17433788
[TBL] [Abstract][Full Text] [Related]
19. [Problems and prospects of non-invasive screening for colorectal cancer].
Maev IV; Govorun VM; Kucheriavyĭ IuA; Golubev NN; Generozov EV; Maslov VV; LiubeznovA IIu; Kostin PA
Klin Med (Mosk); 2009; 87(7):10-6. PubMed ID: 19705783
[TBL] [Abstract][Full Text] [Related]
20. Chemoprevention for colorectal cancer.
Krishnan K; Ruffin MT; Brenner DE
Crit Rev Oncol Hematol; 2000 Mar; 33(3):199-219. PubMed ID: 10789493
[No Abstract] [Full Text] [Related]
[Next] [New Search]
